Rexahn: Fact Sheet (Rexahn Pharmaceuticals, Inc) - Feb 6, 2016 - Anticipated initiation of stage 2 (randomized portion) of P2a trial (NCT02089334) in metastatic renal cell cancer in early 2016; Anticipated interim data from stage 2 (randomized) P2a trial (NCT02089334) in metastatic renal cell cancer in H2 2016;
Anticipated P2a data • Anticipated trial initiation date • Oncology • Renal Cell Carcinoma
|